Literature DB >> 19418101

The lymph node ratio is the strongest prognostic factor after resection of pancreatic cancer.

Hartwig Riediger1, Tobias Keck, Ulrich Wellner, Axel zur Hausen, Ulrich Adam, Ulrich T Hopt, Frank Makowiec.   

Abstract

INTRODUCTION: Survival after surgery of pancreatic cancer is still poor, even after curative resection. Some prognostic factors like the status of the resection margin, lymph node (LN) status, or tumor grading have been identified. However, only few data have been published regarding the prognostic influence of the LN ratio (number of LN involved to number of examined LN). We, therefore, evaluated potential prognostic factors in 182 patients after resection of pancreatic cancer including assessment of LN ratio.
METHODS: Since 1994, 204 patients underwent pancreatic resection for ductal pancreatic adenocarcinoma. Survival was evaluated in 182 patients with complete follow-up evaluations. Of those 182 patients, 88% had cancer of the pancreatic head, 5% of the body, and 7% of the pancreatic tail. Patients underwent pancreatoduodenectomy (85%), distal resection (12%), or total pancreatectomy (3%). Survival was analyzed by the Kaplan-Meier and Cox methods.
RESULTS: In all 204 resected patients, operative mortality was 3.9% (n = 8). In the 182 patients with follow-up, 70% had free resection margins, 62% had G1- or G2-classified tumors, and 70% positive LN. Median tumor size was 30 (7-80) mm. The median number of examined LN was 16 and median number of involved LN 1 (range 0-22). Median LN ratio was 0.1 (0-0.79). Cumulative 5-year survival (5-year SV) in all patients was 15%. In univariate analysis, a LN ratio > or = 0.2 (5-year SV 6% vs. 19% with LN ratio < 0.2; p = 0.003), LN ratio > or = 0.3 (5-year SV 0% vs. 18% with LN ratio < 0.3; p < 0.001), a positive resection margin (p < 0.01) and poor differentiation (G3/G4; p < 0.03) were associated with poorer survival. In multivariate analysis, a LN ratio > or = 0.2 (p < 0.02; relative risk RR 1.6), LN ratio > or = 0.3 (p < 0.001; RR 2.2), positive margins (p < 0.02; RR 1.7), and poor differentiation (p < 0.03; RR 1.5) were independent factors predicting a poorer outcome. The conventional nodal status or the number of examined nodes (in all patients and in the subgroups of node positive or negative patients) had no significant influence on survival. Patients with one metastatic LN had the same outcome as patients with negative nodes, but prognosis decreased significantly in patients with two or more LN involved.
CONCLUSIONS: Not the lymph node involvement per se but especially the LN ratio is an independent prognostic factor after resection of pancreatic cancers. In our series, the LN ratio was even the strongest predictor of survival. The routine estimation of the LN ratio may be helpful not only for the individual prediction of prognosis but also for the indication of adjuvant therapy and herein related outcome and therapy studies.

Entities:  

Mesh:

Year:  2009        PMID: 19418101     DOI: 10.1007/s11605-009-0919-2

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  26 in total

1.  1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience.

Authors:  Jordan M Winter; John L Cameron; Kurtis A Campbell; Meghan A Arnold; David C Chang; Joann Coleman; Mary B Hodgin; Patricia K Sauter; Ralph H Hruban; Taylor S Riall; Richard D Schulick; Michael A Choti; Keith D Lillemoe; Charles J Yeo
Journal:  J Gastrointest Surg       Date:  2006-11       Impact factor: 3.452

2.  Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial.

Authors:  Helmut Oettle; Stefan Post; Peter Neuhaus; Klaus Gellert; Jan Langrehr; Karsten Ridwelski; Harald Schramm; Joerg Fahlke; Carl Zuelke; Christof Burkart; Klaus Gutberlet; Erika Kettner; Harald Schmalenberg; Karin Weigang-Koehler; Wolf-Otto Bechstein; Marco Niedergethmann; Ingo Schmidt-Wolf; Lars Roll; Bernd Doerken; Hanno Riess
Journal:  JAMA       Date:  2007-01-17       Impact factor: 56.272

3.  Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration.

Authors:  T M Breslin; K R Hess; D B Harbison; M E Jean; K R Cleary; A P Dackiw; R A Wolff; J L Abbruzzese; N A Janjan; C H Crane; J N Vauthey; J E Lee; P W Pisters; D B Evans
Journal:  Ann Surg Oncol       Date:  2001-03       Impact factor: 5.344

4.  Pancreaticoduodenectomy with vascular resection: margin status and survival duration.

Authors:  Jennifer F Tseng; Chandrajit P Raut; Jeffrey E Lee; Peter W T Pisters; Jean-Nicolas Vauthey; Eddie K Abdalla; Henry F Gomez; Charlotte C Sun; Christopher H Crane; Robert A Wolff; Douglas B Evans
Journal:  J Gastrointest Surg       Date:  2004-12       Impact factor: 3.452

5.  Long-term results of partial pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head: 25-year experience.

Authors:  Axel Richter; Marco Niedergethmann; Jörg W Sturm; Dietmar Lorenz; Stefan Post; Michael Trede
Journal:  World J Surg       Date:  2003-02-27       Impact factor: 3.352

6.  Standard versus extended lymphadenectomy associated with pancreatoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas: a multicenter, prospective, randomized study. Lymphadenectomy Study Group.

Authors:  S Pedrazzoli; V DiCarlo; R Dionigi; F Mosca; P Pederzoli; C Pasquali; G Klöppel; K Dhaene; F Michelassi
Journal:  Ann Surg       Date:  1998-10       Impact factor: 12.969

7.  Prognosis of patients with colorectal cancer is associated with lymph node ratio: a single-center analysis of 3,026 patients over a 25-year time period.

Authors:  Robert Rosenberg; Jan Friederichs; Tibor Schuster; Ralf Gertler; Matthias Maak; Karen Becker; Anne Grebner; Kurt Ulm; Heinz Höfler; Hjalmar Nekarda; Jörg-Rüdiger Siewert
Journal:  Ann Surg       Date:  2008-12       Impact factor: 12.969

8.  Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients.

Authors:  Jonathan E Lim; Michael W Chien; Craig C Earle
Journal:  Ann Surg       Date:  2003-01       Impact factor: 12.969

9.  Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma, part 2: randomized controlled trial evaluating survival, morbidity, and mortality.

Authors:  Charles J Yeo; John L Cameron; Keith D Lillemoe; Taylor A Sohn; Kurtis A Campbell; Patricia K Sauter; JoAnn Coleman; Ross A Abrams; Ralph H Hruban
Journal:  Ann Surg       Date:  2002-09       Impact factor: 12.969

10.  Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma--part 3: update on 5-year survival.

Authors:  Taylor S Riall; John L Cameron; Keith D Lillemoe; Kurtis A Campbell; Patricia K Sauter; JoAnn Coleman; Ross A Abrams; Daniel Laheru; Ralph H Hruban; Charles J Yeo
Journal:  J Gastrointest Surg       Date:  2005-12       Impact factor: 3.267

View more
  114 in total

1.  Multi-institutional analysis of pancreatic adenocarcinoma demonstrating the effect of diabetes status on survival after resection.

Authors:  Robert M Cannon; Ryan LeGrand; Ryaz B Chagpar; Syed A Ahmad; Rebecca McClaine; Hong Jin Kim; Christopher Rupp; Cliff S Cho; Adam Brinkman; Sharon Weber; Emily R Winslow; David A Kooby; Carrie K Chu; Charles A Staley; Ian Glenn; William G Hawkins; Alexander A Parikh; Nipun B Merchant; Kelly M McMasters; Robert C G Martin; Glenda G Callender; Charles R Scoggins
Journal:  HPB (Oxford)       Date:  2012-01-19       Impact factor: 3.647

2.  Potential contribution of preoperative neoadjuvant concurrent chemoradiation therapy on margin-negative resection in borderline resectable pancreatic cancer.

Authors:  Chang Moo Kang; Yong Eun Chung; Jeong Youp Park; Jin Sil Sung; Ho Kyoung Hwang; Hye Jin Choi; Hyunki Kim; Si Young Song; Woo Jung Lee
Journal:  J Gastrointest Surg       Date:  2011-12-20       Impact factor: 3.452

3.  Prognostic impact of para-aortic lymph node metastasis in pancreatic ductal adenocarcinoma.

Authors:  Yoshiaki Murakami; Kenichiro Uemura; Takeshi Sudo; Yasushi Hashimoto; Yoshio Yuasa; Taijiro Sueda
Journal:  World J Surg       Date:  2010-08       Impact factor: 3.352

4.  Extended pancreatic resections and lymphadenectomy: An appraisal of the current evidence.

Authors:  Shailesh V Shrikhande; Savio G Barreto
Journal:  World J Gastrointest Surg       Date:  2010-02-27

Review 5.  The lymphatic system and pancreatic cancer.

Authors:  Darci M Fink; Maria M Steele; Michael A Hollingsworth
Journal:  Cancer Lett       Date:  2015-12-29       Impact factor: 8.679

Review 6.  Prognostic factors related with survival in patients with pancreatic adenocarcinoma.

Authors:  Ahmet Bilici
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

7.  N0/N1, PNL, or LNR? The effect of lymph node number on accurate survival prediction in pancreatic ductal adenocarcinoma.

Authors:  Nakul P Valsangkar; Devon M Bush; James S Michaelson; Cristina R Ferrone; Jennifer A Wargo; Keith D Lillemoe; Carlos Fernández-del Castillo; Andrew L Warshaw; Sarah P Thayer
Journal:  J Gastrointest Surg       Date:  2012-12-11       Impact factor: 3.452

8.  Redefining the R1 resection for pancreatic ductal adenocarcinoma: tumour lymph nodal burden and lymph node ratio are the only prognostic factors associated with survival.

Authors:  Biku J John; Prashant Naik; Alastair Ironside; Brian R Davidson; Guiseppe Fusai; Roopinder Gillmore; Jennifer Watkins; Sakhawat H Rahman
Journal:  HPB (Oxford)       Date:  2013-01-14       Impact factor: 3.647

9.  Accurate prediction of nodal status in preoperative patients with pancreatic ductal adenocarcinoma using next-gen nanoparticle.

Authors:  Shaunagh McDermott; Sarah P Thayer; Carlos Fernandez-Del Castillo; Mari Mino-Kenudson; Ralph Weissleder; Mukesh G Harisinghani
Journal:  Transl Oncol       Date:  2013-12-01       Impact factor: 4.243

10.  Lymph node ratio versus number of affected lymph nodes as predictors of survival for resected pancreatic adenocarcinoma.

Authors:  Imran Bhatti; Oliver Peacock; Altaf K Awan; David Semeraro; Michael Larvin; Richard I Hall
Journal:  World J Surg       Date:  2010-04       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.